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Abstract
Background: HIV-1 and all retroviruses are related to retroelements of simpler organisms such
as the yeast Ty elements. Recent work has suggested that the yeast retroelement Ty1 replicates
via an unexpected RNA lariat intermediate in cDNA synthesis. The putative genomic RNA lariat
intermediate is formed by a 2'-5' phosphodiester bond, like that found in pre-mRNA intron lariats
and it facilitates the minus-strand template switch during cDNA synthesis. We hypothesized that
HIV-1 might also form a genomic RNA lariat and therefore that siRNA-mediated inhibition of
expression of the human RNA lariat de-branching enzyme (DBR1) expression would specifically
inhibit HIV-1 replication.
Results: We designed three short interfering RNA (siRNA) molecules targeting DBR1, which
were capable of reducing DBR1 mRNA expression by 80% and did not significantly affect cell
viability. We assessed HIV-1 replication in the presence of DBR1 siRNA and found that DBR1
knockdown led to decreases in viral cDNA and protein production. These effects could be
reversed by cotransfection of a DBR1 cDNA indicating that the inhibition of HIV-1 replication was
a specific effect of DBR1 underexpression.
Conclusion: These data suggest that DBR1 function may be needed to debranch a putative HIV-
1 genomic RNA lariat prior to completion of reverse transcription.
Background
Retrotransposons resemble retroviruses and contain long
terminal repeats (LTR). They are mobile DNA elements
that replicate via RNA intermediates. The Ty1 retroele-
ment is among the best characterized of the retrotrans-
posons of the yeast Saccharomyces cerevisiae [1-3]. Using a
genetic screen aimed at identifying cellular factors
involved in Ty1 transposition, Chapman and Boeke
found that S. cerevisiae DBR1 mutants had lower Ty1
transposition frequency and were viable [4]. Dbr1 protein
is a 2'-5' phosphodiesterase that cleaves intron RNA lariat
branch points after splicing, facilitating ribonucleotide
turnover [4,5]. DBR1 mutants produce mature mRNA, but
accumulate intron lariats [3,4]. Mutations in DBR1
inhibit both Ty1 transposition and cDNA formation.
Cheng and Menees provided evidence that Ty1 transcripts
contain a 2'-5' branch characteristic of an RNA lariat, and
demonstrated that the genomic RNA lariat is an unantici-
pated intermediate in the life cycle of Ty1 [2]. The location
of this branch suggests that it may play a role during the
formation of Ty1 cDNA by facilitating the transfer of nas-
cent minus-strand of Ty1 cDNA from the upstream region
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of the Ty1 RNA template to the downstream region [2,3].
The similarity of Ty1 to animal retroviruses further sug-
gests that the branch may be widely conserved among ret-
roviruses as well as retroelements.
Human immunodeficiency virus (HIV) reverse transcrip-
tion of the RNA genome into DNA is performed by the
viral enzyme reverse transcriptase (RT). The primer for
reverse transcription is a cellular tRNA. Retroviruses, long
terminal repeat (LTR) retrotransposons, and long inter-
spersed nucleotide element retrotransposons use cellular
tRNAs to initiate cDNA synthesis [6-8]. Different tRNAs
are used by different retroviruses and retrotransposons
[9]. Early in the viral life cycle, the tRNA primes minus-
strand strong-stop DNA synthesis, whereby the 5' end of
the viral positive sense RNA genome is copied into minus-
strand cDNA by RT, while the RNA template is degraded
by the RNAse-H activity of RT. After minus-strand strong-
stop DNA synthesis, a template shift from the 5' LTR to the
3' LTR is required to continue synthesis of the complete
minus-strand cDNA, a requirement for converting the
viral RNA genome into the proviral DNA genome. This
"template switch" is required to synthesize the complete
DNA genome, but its precise mechanism has never been
identified. The recent work of Menees and colleagues
showed that the 5' nucleotide (nt) of Ty1 RNA forms a 2'-
5' bond with a nt at the beginning of R region in the 3' LTR
of the same RNA, creating a lariat. The properties of the
lariat suggest it forms by a novel mechanism and that
branching and debranching may play roles in Ty1 reverse
transcription at the minus-strand transfer step.
RNAi is a mechanism of gene silencing that has been
widely used to study gene function in vitro [10-14]. RNAi
occurs in cells via complex endogenous machinery that
recognizes double stranded RNA, cleaves it into small
fragments (19–21 nucleotides), and then uses those frag-
ments as guides to specifically degrade RNA species dis-
playing complementary sequence. The small fragments,
called short interfering RNA (siRNA), can be introduced
directly into mammalian cells to enter this pathway to
induce the specific degradation of intracellular RNA.
SiRNA-induced RNAi mediated degradation of DBR1
mRNA was used to study the role of DBR1 protein in HIV-
1 replication.
Results
Transfection of GHOST cells with DBR1 siRNAs resulted in 
suppression of DBR1 mRNA
Three DBR1 siRNAs, targeted to DBR1 sequence positions
215 to 235, 436 to 456 and 971 to 991 were designed and
inserted into pHyper (analogous to pSuper, obtained
from Dr. V. Planelles of the University of Utah). For each
DBR1 siRNA expression plasmid, two 64 nucleotide (nt)
oligonucleotides were annealed to create 5' Bgl-II and 3'
Hind III sites flanking a 21 nt target sequence in the DBR1
gene, a central 9 nt loop followed by a 21 nt antisense
copy of the target sequence. The annealed 64 mers were
cloned between the Bgl-II and Hind-III sites of the pHyper
vector, as previously described for pSuper [15]. These
three DBR1 siRNA plasmids were designated pHyper-D1,
pHyper-D2 and pHyper-D3.
GHOST-R5X4 cells were transfected with various amounts
of all three DBR1 siRNA expression plasmids combined in
equal proportions (pHyper-D123) or control vector pHy-
per for forty-eight hours with Lipofectamine. To evaluate
the effects of DBR1 siRNA, total RNA was extracted and
real-time quantitative RT-PCR was performed with DBR1
specific primers. The DBR1 mRNA level was downregu-
lated to a maximum of 80% following transfection with
12.8 µg/ml pHyper-D123 (Fig 1A). Next we examined the
kinetics of DBR1 mRNA knockdown in GHOST-R5X4
cells transfected with each DBR1 siRNA plasmid sepa-
rately (pHyper-D1, pHyper-D2, pHyper-D3) or together
(pHyper-D123) compared to cells transfected with the
control vector pHyper. We analyzed DBR1 message levels
at various time points post-transfection by real-time quan-
titative RT-PCR. The data revealed that transfection of cells
with any of the three DBR1 siRNA expression plasmids
resulted in a reduction in the amount of DBR1 mRNA
compared to cells transfected with the control vector pHy-
per (Fig 1B). This effect was maximal forty-eight hours
post-transfection. Moreover, we found that the mixture of
all three DBR1 siRNA expressing plasmids was the most
effective and reduced the DBR1 mRNA level by more than
80%.
Knockdown of DBR1 or over expression of DBR1 is not 
toxic to cells
We used a commercial assay of cellular mitochondrial
metabolism to determine whether DBR1 siRNA or DBR1
cDNA expression had adverse or cytotoxic effects.
GHOST-R5X4 cells were transfected with pHyper-D123
and pHyper as a control or CDM9-DBR1 and CDM9 as a
control. Forty-eight hours later, we assayed mitochondrial
electron transport by its ability to reduce the tetrazolium
salt, MTS, to produce formazan using a commercial kit.
We did not detect significant cytotoxic effects following
the addition of 3.2, 6.4, 12.8, 25.6, or 51.2 µg/ml of DBR1
siRNA pHyper-D123 and 1, 4, or 6 µg/ml of CDM9-DBR1
compared to the same concentration of each control plas-
mid (Fig 2).
DBR1 knockdown inhibits HIV-1 replication in GHOST 
cells
To test whether DBR1 siRNA was capable of inhibiting
HIV-1 replication, GHOST-R5X4 cells were transfected
with pHyper-D1, pHyper-D2, pHyper-D3, pHyper-D123
or pHyper alone for forty-eight hours, then infected withRetrovirology 2005, 2:63 http://www.retrovirology.com/content/2/1/63
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R5-HIV-1 (JR-CSF). Twenty-four hours after HIV-1 infec-
tion, cell supernatants were collected to detect extracellu-
lar HIV-1 by ELISA for the viral capsid protein, p24. These
data showed more than a 70% decrease in HIV-1 replica-
tion in GHOST-R5X4 cells expressing three DBR1 siRNA
Suppression of DBR1 mRNA expression by DBR1 siRNA Figure 1
Suppression of DBR1 mRNA expression by DBR1 
siRNA. (A) GHOST-R5X4 cells were transfected with vari-
ous concentrations of DBR1 siRNA pHyper-D123 (0.8 µg/
ml, 1.6 µg/ml, 3.2 µg/ml, 6.4 µg/ml, 12.8 µg/ml) or mock 
transfected. Forty-eight hours post transfection, RNA was 
isolated, treated with Dnase I and used as template in real-
time quantitative RT-PCR. Each reaction included 300 ng 
RNA, 0.5 µM each gene-specific primer for DBR1 and 
GAPDH amplification. GAPDH was used as an internal con-
trol. (B) GHOST-R5X4 cells were transfected with 12.8 µg/
ml DBR1 siRNA pHyper-D1, pHyper-D2, pHyper-D3, pHy-
per-D123 or control pHyper and cells were collected at the 
indicated time points. RNA was isolated, treated with Dnase 
I and analyzed by real-time quantitative RT-PCR. Results 
shown are from triplicate samples in a representative experi-
ment. Error bars indicate standard deviations. Results that 
are significant by Student's t-test are indicated by asterisks (p 
< 0.05).
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Determination of cell viability Figure 2
Determination of cell viability. (A) GHOST-R5X4 cells 
were transfected with 3.2 µg/ml, 6.4 µg/ml, 12.8 µg/ml, 25.6 
µg/ml or 51.2 µg/ml DBR1 siRNA pHyper-D123 (black bars) 
or the same concentrations of pHyper alone (white bars) as a 
control. (B) GHOST-R5X4 cells were transfected with 1 µg/
ml, 4 µg/ml, 6 µg/ml CDM9-DBR1 (black bars) or the same 
concentrations of CDM9 alone (white bars) as a control. 
After forty-eight hours cellular viability was assayed with a 
commercial MTS assay kit (Promega). Results shown are 
from triplicate samples in a representative experiment. Error 
bars indicate standard deviations.
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molecules compared to vector transfected cells (Fig 3). We
also measured HIV-1 p24 in cell supernatants that were
collected two and three days post-infection. Less suppres-
sion of viral replication was observed at these times, how-
ever, probably because the levels of DBR1 mRNA had
returned to near normal (Fig. 1B and data not shown).
DBR1 over-expression counteracts the effect of DBR1 
siRNA on HIV-1 replication
We next queried whether DBR1 over-expression would
affect HIV-1 replication alone or when cotransfected with
DBR1 siRNA. GHOST-R5X4 cells were transfected with a
human DBR1 cDNA expressed by the plasmid vector,
CDM9 at three concentrations or with vector alone. RNA
was extracted forty-eight hours later and quantified by
real-time quantitative RT-PCR with DBR1 specific primers
(Fig. 4A). We observed a dose dependent increase in
DBR1 mRNA expression as expected. Subsequently,
GHOST-R5X4 cells were transfected with CDM9-DBR1,
control vector CDM9, or DBR1 siRNA pHyper-D123, con-
trol vector pHyper or cotransfected with CDM9-DBR1 and
DBR1 siRNA pHyper-D123, control vector CDM9 and
pHyper, for forty-eight hours and then infected with HIV-
1 (JR-CSF). To evaluate HIV-1 replication, the superna-
tants were analyzed twenty-four hours post infection for
the presence of viral capsid, p24, with a commercial ELISA
kit (Fig. 4B). We did not observe a significant effect of
DBR1 overexpression on HIV-1 replication in GHOST-
R5X4 cells. In contrast, the three DBR1 siRNA's
DBR1 siRNA inhibition of HIV-1 replication Figure 3
DBR1 siRNA inhibition of HIV-1 replication. GHOST-
R5X4 cells were transfected with 12.8 µg/ml DBR1 siRNA 
pHyper-D1, pHyper-D2, pHyper-D3, pHyper-D123 or con-
trol pHyper. Forty-eight hours later, cells were infected with 
HIV-1 (JR-CSF) for twenty-four hours and p24 in superna-
tants was analyzed using a commercial HIV-1 p24 ELISA kit. 
All ELISA measurements were done in triplicate. Error bars 
indicate +/- standard deviation. Results marked with an aster-
isk are significant by Student's t-test (p < 0.05).
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DBR1 over-expression does not affect HIV-1 replication Figure 4
DBR1 over-expression does not affect HIV-1 replica-
tion. (A) GHOST-R5X4 cells were transfected with various 
amounts of CDM9-DBR1 (1 µg/ml, 4 µg/ml, 6 µg/ml) or 
mock transfected for forty-eight hours. Total RNA was iso-
lated and DBR1 expression was quantified by real-time RT-
PCR. (B) GHOST-R5X4 cells were transfected with CDM9-
DBR1 (black bar, CDM9-DBR1), control vector CDM9 
(white bar, CDM9-DBR1) or DBR1 siRNA pHyper-D123 
(black bar, DBR1 siRNA), control vector pHyper (white bar, 
DBR1 siRNA), or cotransfected CDM9-DBR1 and DBR1 
siRNA pHyper-D123 (black bar, CDM9-DBR1 + DBR1 
siRNA), control vector CDM9 and pHyper (white bar, 
CDM9-DBR1 + DBR1 siRNA) for forty-eight hours and then 
infected with HIV-1 (JR-CSF) for twenty-four hours. Super-
natants were collected and p24 was assayed using a commer-
cially available HIV-1 p24 ELISA kit. All ELISA measurements 
were done in triplicate. Error bars indicate standard devia-
tions. The asterisk denotes p < 0.05 by Student's t-test.
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significantly repressed HIV-1 replication and this inhibi-
tion could be reversed by cotransfection of DBR1 cDNA.
This indicates that the DBR1 siRNA inhibited HIV-1 repli-
cation specifically, by lowering DBR1 expression.
DBR1 siRNA suppresses HIV-1 replication during reverse 
transcription
To more precisely determine the stage at which HIV-1 rep-
lication is inhibited by degradation of DBR1 mRNA, we
transfected GHOST-R5X4 cells with DBR1 siRNA pHyper-
D123 or control vector pHyper for forty-eight hours, then
infected the cells with HIV-1, and harvested them twenty-
four hours post-infection. The cells were lysed and DNA
was isolated to evaluate the synthesis of HIV-1 cDNA by
real-time quantitative PCR. The oligonucleotide primers
M667 and AA55 specific for the R and U5 regions of the
HIV-1 LTR respectively were used to detect early reverse
transcription products, also known as strong-stop DNA,
env primers Env1 and Env2 were used to detect intermedi-
ate reverse transcription products, while the LTR-R region
and gag primers M667 and M661 were chosen to detect
completely synthesized viral cDNA (Fig. 5A). Copies of
HIV-1 were normalized against copies of β-globin to con-
trol for differences in cell number between samples. The
results showed that early, products of reverse transcription
were differentially affected by expression of DBR1 siRNA
compared to intermediate and late reverse transcription
products. The accumulation of HIV-1 strong-stop DNA
was not affected by DBR1 siRNA expression (Fig. 5B),
while the level of intermediate length and complete HIV-
1 cDNA molecules was decreased similarly in the presence
of DBR1 siRNA twenty-four hours post-infection (Fig.
5C,5D). This difference implies that the lariat debranch-
ing activity of DBR1 is needed after strong-stop DNA syn-
thesis but prior to reverse transcription of the env gene or
the completion of reverse transcription. To assay the spe-
cificity of inhibition of HIV-1 reverse transcription by
DBR1 siRNA, we transfected GHOST-R5X4 cells with
CDM9-DBR1, control vector CDM9 or with DBR1 siRNA
pHyper-D123, control vector pHyper or cotransfected
with CDM9-DBR1 and DBR1 siRNA pHyper-D123 or
control vector CDM9 and pHyper for forty-eight hours
and then infected with HIV-1 (JR-CSF). As shown in Fig 5,
DBR1 over-expression did not significantly affect HIV-1
reverse transcription. Moreover, the effect of DBR1 siRNA
expression on HIV-1 cDNA synthesis could be reversed by
cotransfection of a DBR1 cDNA. This result indicates that
the inhibition of HIV-1 reverse transcription by DBR1
siRNA was mediated specifically, by suppression of DBR1
expression.
Discussion
SiRNAs are widely used for targeting and silencing genes
by RNA interference. The recent discovery that exoge-
nously delivered siRNA can trigger RNAi in mammalian
cells allows the use of this technology in research and
perhaps eventually as a therapeutic tool. Inhibition of
HIV-1 replication with RNAi has already been demon-
strated with siRNAs against a variety of structural or regu-
latory genes including gag, pol, nef, vif, tat, env and rev [16-
22]. These results demonstrate that siRNA directed to an
HIV-1-specific gene could inhibit viral replication. In
addition to targeting viral genes, many studies also inves-
tigated the efficacy of siRNAs in down regulating host cell
molecules necessary for HIV-1 infection [23-28]. An
advantage in targeting the interaction of cellular mole-
cules with HIV-1 is that broad-spectrum efficacy against
all clades of HIV-1 might be more readily achievable and
the frequency of escape mutants might be lower. In this
report, we have shown that siRNAs targeted to the host
cellular gene DBR1 specifically decreased the amount of
HIV-1 cDNA and capsid protein produced.
It has been previously found that the yeast gene DBR1
affects Ty1 transposition [1,4,29]. This gene encodes the
RNA debranching enzyme, which hydrolyzes the 2'-5'
bonds of intron RNA lariat branch points. A recent report
suggested that the debranching enzyme influences Ty1
transposition because the Ty1 genomic RNA forms a lariat
intermediate during cDNA synthesis [2]. This lariat inter-
mediate was proposed to be formed by a 2'-5' phosphodi-
ester bond between the 5' end of the genome and the first
nucleotide in the 3' R region. Since retroviruses like HIV-
1 and retroelements of Saccharomyces cerevisiae like Ty1
replicate via similar mechanisms and have similar LTR
structures, we tested whether reduction in human DBR1
affected HIV-1 replication. We used three DBR1 siRNAs to
specifically degrade DBR1 mRNA and measured the
effects of DBR1 down regulation on HIV-1 replication.
We demonstrated that DBR1 siRNA expression reduced
the level of DBR1 mRNA in a dose and time dependent
manner and decreased the amount of virus produced
from infected cells. This DBR1 siRNA-mediated inhibition
of HIV-1 replication occurred after strong-stop DNA for-
mation but prior to reverse transcription of the env gene or
the completion of minus-strand synthesis. We found that
DBR1 siRNA inhibited the formation of env gene cDNA
and complete HIV-1 cDNA twenty-four hours post-infec-
tion (Fig. 5). In contrast, there was little effect on the syn-
thesis of minus-strand strong-stop DNA. To determine if
the lack of virus production and inhibition of reverse
transcription were specifically due to DBR1 siRNA, we
transfected DBR1 cDNA alone or with DBR1 siRNA and
analyzed HIV replication. DBR1 over-expression alone
had little effect on HIV-1 replication but it blocked the
inhibitory effect of DBR1 siRNA when cotransfected.
These results demonstrate the specific inhibition of HIV-1
reverse transcription by DBR1 siRNA after strong-stop
DNA formation – perhaps during the minus-strandRetrovirology 2005, 2:63 http://www.retrovirology.com/content/2/1/63
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DBR1 siRNA suppresses HIV-1 reverse transcription after minus-strand strong-stop DNA formation Figure 5
DBR1 siRNA suppresses HIV-1 reverse transcription after minus-strand strong-stop DNA formation. (A) Loca-
tion of primers. The oligonucleotide primers M667/AA55 specific for the R/U5 region of the LTR were used to detect early 
reverse transcripts (strong-stop DNA) (B) and env primers Env1/Env2 to were used detect intermediate reverse transcripts 
(C). LTR/gag primers M667/M661 were chosen to detect complete first-strand viral cDNA (D). In B, C and D, GHOST-R5X4 
cells were transfected with DBR1 siRNA pHyper-D123 (black bars, siRNA), control vector pHyper (white bars, siRNA) or 
CDM9-DBR1 (black bars, cDNA), control vector CDM9 (white bars, cDNA) or co-transfected with CDM9-DBR1 and DBR1 
siRNA pHyper-D123 (black bars, siRNA + cDNA), control vectors CDM9 and pHyper (white bars, siRNA + cDNA) for forty-
eight hours, followed by infection with Dnase-treated HIV-1 (JR-CSF). Twenty-four hours later, the cells were lysed and DNA 
was isolated for real time quantitative PCR to evaluate the synthesis of HIV-1 cDNA. Copies of HIV-1 DNA were normalized 
against copies of β-globin. Error bars indicate standard deviations. Asterisks denote p < 0.05 by Student's t-test.
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template switch. Nevertheless, we cannot exclude sup-
pression of viral replication at other stages after strong-
stop DNA formation.
In summary, our studies show that siRNA targeted to the
human DBR1 gene specifically inhibited HIV-1 replica-
tion during reverse transcription. Although we do not
know the role of the putative HIV-1 genomic RNA lariat in
viral replication, it is likely that further investigation with
DBR1 siRNA will provide insights into the mechanism of
HIV-1 cDNA synthesis.
Conclusion
We have demonstrated that suppression of the host RNA
lariat de-branching enzyme (DBR1) with siRNA specifi-
cally inhibits HIV-1 replication. Further studies showed
DBR1 siRNA suppresses HIV-1 replication during reverse
transcription. A recent report found that the minus-strand
template switch in the yeast retroelement Ty1 is accom-
plished via an RNA lariat intermediate, which is formed
by a 2'-5' phosphodiester bond between the 5' end and 3'
LTR of the genomic RNA. HIV-1 is similar to retroele-
ments like Ty1and our results suggest that HIV-1 may uti-
lize a similar RNA lariat intermediate during minus-strand
transfer. This finding may have profound implications for
the development of new therapeutics for AIDS.
Methods
Construction of siRNA expression vectors
The mammalian expression vector, pHyper (analogous to
pSuper) was obtained from Dr. Vicente Planelles of the
University of Utah and used for expression of siRNA. For
each siRNA expression plasmid, a pair of 64 nucleotide
oligonucleotides were annealed to create a 5' Bgl-II and 3'
Hind III site flanking a 21 nt target sequence in the DBR1
gene, a central 9 nt loop followed by a 21 nt antisense
copy of the target sequence. Three pairs of cDNA oligonu-
cleotides, targeting the human DBR1 gene at different
locations were synthesized by MWG Biotech (Irvine, CA).
Each pair of oligonucleotides was annealed at 90°C for 4
minutes, then at 70°C for 10 minutes, cooled to 37°C,
and incubated for 20 minutes. The annealed dsDNA oli-
gonucleotides were ligated into the pHyper vector
between the Bgl-II and Hind III sites. These three 21 nt
DBR1 sequences, D1, AACGAGGCGGATCTACGCTGC;
D2, AAGGATCGGTGGAATCTCTGG; D3,
AATGTGACTGGGCGCCTGTGG, were used to create
three DBR1-siRNA plasmids, designated pHyper-D1, D2
and D3.
Cell culture, DNA transfection, viral stock preparation and 
infection
GHOST-R5X4 cells were cultured in Iscove's modified
Dulbecco's medium (IMDM) containing 10% fetal
bovine serum (FBS), 50 µg/ml gentamicin and 500 µg/ml
of G418. Human embryonic kidney 293T cells were cul-
tured in Dulbecco's modified Eagle medium (DMEM)
supplemented with 10% FBS and 50 µg/ml gentamicin.
GHOST-R5X4 cells were plated at 95% confluency for
transfection and transfected using Lipofectamine (Invitro-
gen) according to the manufacturer's instructions. Forty-
eight hours after transfection, cells were collected. Viral
stocks were prepared by transfecting 293T cells (seeded at
9 × 106 cells per T75 flask) with 100 µg of πSV-JR-CSF plas-
mid coprecipitated with calcium phosphate. Two days
post-transfection, culture supernatant was collected and
frozen at -80°C until needed. HIV-1 virions in the super-
natant were quantified using HIV-1 p24 ELISA kit (Perkin
Elmer).
Cell viability assay
Cell viability assays were conducted with CellTiter 96
aqueous cell proliferation assay kit (Promega) according
to the manufacturer's specifications. Briefly, cells were
plated into flat-bottom 96-well plates at a density of 2 ×
103 cells/well and allowed to attach overnight. Cells were
then transfected with different concentrations of pHyper-
DBR1 siRNA and pHyper as a control or CDM9-DBR1 and
CDM9 as a control. After forty-eight hours of incubation,
20 µL of MTS reagent was added to each well, the plate
was incubated for three hours at 37°C. A 490 nm absorb-
ance value was determined using a Model-550 ELISA plate
reader (Beckman Instruments Inc.). The percentage of via-
ble cells was calculated as: (Abssample - Absblank)/(Abscontrol -
Absblank) × 100.
RNA isolation and real-time quantitative RT-PCR
Total RNA was isolated using Trizol reagent (Life Technol-
ogies) according to the manufacturer's instructions. The
amount of extracted RNA was quantified by measuring
the absorbance at 260 nm. One microgram of RNA was
treated with 1 unit Dnase I (Invitrogen) in a volume of 10
µl to remove contaminating DNA (37°C for 15 min,
75°C for 5 min). Three hundred ng of Dnase I treated
RNA was reverse transcribed using a two-step reverse tran-
scription kit (Applied Biosystems) in a final volume of 10
µl. Reverse transcription was performed for 60 min at
37°C. The total cDNA volume of 10 µl was frozen until
real-time quantitative PCR was performed. After thawing
for PCR experiments, the cDNA was diluted in 90 µl of
distilled water and 2 µl of diluted cDNA was used for each
PCR reaction. Real-time quantitative PCR was performed
using ABI Prism 7700 sequence detection system, (PE
Applied Biosystems) for amplification and detection. PCR
conditions were as follows: initial denaturation at 95°C
for 10 min then 40 rounds of cycling at 95°C for 15 sec
and 60°C for 60 sec. Each PCR reaction in triplicate con-
tained 15 µl SYBR green PCR master mix (Applied Biosys-
tems), and 0.3 µM of each gene-specific primer for human
DBR1 and glyceraldehyde-3-phosphate-dehydrogenaseRetrovirology 2005, 2:63 http://www.retrovirology.com/content/2/1/63
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(GAPDH) in a 30 µl reaction volume. Forward and reverse
primer sequences for amplifying DBR1 were GGAAAC-
CATGAAGCCTCAAA (nt 247–266) and CCGATCCTTA-
CACCTCGGTA (nts 444–425), respectively. Forward and
reverse primer sequences for amplifying GAPDH were
GGTGGTCTCCTCTGACTTCAA (nt 840–860) and GTT-
GCTGTAGCCAAATTCGTTGT (nt 966–944). A normal-
ized DBR1 value was calculated by dividing the DBR1
copy number (determined from the appropriate standard
curve) by the GAPDH (endogenous reference) copy
number.
P24 ELISA
HIV-1 p24 ELISA was performed using a commercially
available kit (Perkin Elmer) according to the manufac-
turer's instructions. For measuring p24 in the superna-
tants, 103 fold dilutions of the supernatants were used. All
ELISA measurements were done in triplicate.
Quantitative real-time PCR
At each time point, 3.0 × 106 cells were lysed in 100 µl of
100 µg/ml proteinase K in 10 mM Tris-HCl, pH 8.0 at
56°C for 1 hour, followed by heat inactivation at 95°C for
10 min. Each PCR reaction contained 15 µl SYBR green
PCR master mix (Applied Biosystems), 5 µl of cell lysate,
0.3 µM of each primer in a 30 µl reaction volume. HIV-1
specific primers AA55, CTGCTAGAGATTTTCCACACT-
GAC (nts 635–612) and M667, GGCTAACTAGGGAAC-
CCACTG (nts 496–516) were used to detect minus strand
strong stop. Env1, GGCAGGGATACTCACCCTTATCG
(nts 8337–8360) and Env2, GGATTTCCCACCCCCT-
GCGTCCC (nts 8590–8566) were used to detect interme-
diate lengthe reverse transcription products. M661,
CCTGCGTCGAGAGAGAGCTCCTCTGG (nts 695–672)
and M667 were used to detect complete synthesis of first-
strand cDNA. Copies of HIV-1 DNA were normalized
against copies of β-globin using primers LA1 globin,
ACACAACTGTGTTCACTAGC and LA2 globin, CAACT-
TCATCCACGTTCACC directed to β-globin [30].
DBR1 cDNA isolation and expression
A 1.7 kb cDNA fragment encoding human DBR1 was
amplified by PCR from a human PHA-stimulated T cell
cDNA library [31]. Amplification reactions were per-
formed in a 25 µl mixture containing 0.625 Units FailSafe
PCR Enzyme Mix (Epicentre), 500 nM forward
(GAATTCGCCACCATGCGGGTGGCTGTGGCTGGCT-
GCTGCCACGG) and reverse (AACAAGTAAATCATCT-
TAAGCTGCATCG) primers in FailSafe PCR Premix-E
buffer. The amplification reactions were carried out with
the following program: one cycle of 2 min at 92°C, 35
cycles consisting of 30 sec at 95°C, 1 min at 55°C, 2 min
at 72°C and a final extension step of 10 min at 72°C. PCR
products were separated on 1% agarose gel pre-stained
with ethidium bromide. A gel cleanup kit (Eppendorf)
was used to purify and elute the PCR product DNA frag-
ment for cloning and sequencing. The fragment was
inserted between the Xho1 and Not1 sites of CDM9 and
the sequence was found to be identical to the DBR1
sequence in the NCBI database. CDM9 is a derivative of
CDM8 that contains a larger region of the human CMV
immediate early region including the first intron and non-
coding exon [32]. Various amounts of CDM9-DBR1 (1, 4
and 6 µg/ml) were used to transfect GHOST-R5X4 cells
with Lipofectamine (Invitrogen) according to manufac-
turer's instructions, CDM9 alone was used as a control.
Total cellular RNA was extracted and real-time quantita-
tive RT-PCR was performed to quantify DBR1 expression.
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